

1 **Metabolomics of IgE-Mediated Food Allergy and Oral Immunotherapy Outcomes based on**
2 **Metabolomic Profiling**

3 **Authors: Yamini V. Virkud,^{1,2,3,4} Jennifer N. Styles¹, Rachel S. Kelly,^{3,4} Sarita U. Patil^{2,3,5}, Bert**
4 **Ruiter^{2,3}, Neal P. Smith², Clary Clish,⁵ Craig E. Wheelock,⁶ Juan C. Celedón,⁷ Augusto A.**
5 **Litonjua,^{3,4} Supinda Bunyavanich,⁸ Scott T. Weiss,^{3,4} Erin S. Baker,⁹ Jessica A. Lasky-Su*,^{3,4}**
6 **Wayne G. Shreffler*^{2,3,5}**

7 ***co-senior authorship**

8 **Affiliations:**

- 9 1. University of North Carolina, Chapel Hill. Department of Pediatrics, Division of Allergy and
10 Immunology, Food Allergy Initiative. Chapel Hill, NC
- 11 2. Massachusetts General Hospital for Children, Food Allergy Center. Department of Pediatrics,
12 Massachusetts General Hospital, Boston, MA
- 13 3. Harvard Medical School, Boston, MA
- 14 4. Channing Division of Network Medicine, Brigham & Women's Hospital, Boston, MA
- 15 5. Broad Institute, Cambridge, MA
- 16 6. Karolinska University Hospital, Unit of Integrative Metabolomics, Institute of Environmental
17 Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and
18 Allergy. Stockholm, Sweden.
- 19 7. Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center. Division of
20 Pulmonary Medicine. University of Pittsburgh, Pittsburgh, PA 15260, USA
- 21 8. Icahn School of Medicine at Mount Sinai. Department of Genetics & Genomic Sciences and
22 Department of Pediatrics. New York, NY
- 23 9. University of North Carolina, Chapel Hill. Department of Chemistry. Chapel Hill, NC

24
25

26 **Corresponding author:**

27 Yamini V. Virkud, virkud@unc.edu
28 University of North Carolina
29 101 Manning Drive, CB#7231
30 Chapel Hill, NC 27599-7231

31

32 **Clinical Trial or Protocol number associated with this study:** NCT01324401 (PNOIT),
33 NCT00920621 (VDAART)

34 **Conflicts of Interest:** JLS is a scientific consultant to Precion Inc. and TruDiagnostic Inc. AAL
35 contributes to UpToDate, Inc. – author of online education, royalties totaling not more than \$3000 per
36 year. STW receives royalties from UpToDate and is on the board of Histolix a digital pathology
37 company. JCC has received research materials (inhaled steroids) from Merck, in order to provide
38 medications free of cost to participants in an NIH-funded study, unrelated to the current work. The
39 remaining authors have no conflicts of interest to disclose.

40

41 **Funding/Acknowledgments:** The Genetics of Asthma in Costa Rica Study was supported by the
42 National Institutes of Health (Grants HL066289, P01HL13225, R01HL123915). Vitamin D Antenatal
43 Asthma Reduction Trial (VDAART) was supported by R01HL123546, R01HL091528, U01HL091528,
44 and UH3ODO023268 from the National Heart, Lung, and Blood Institute (NHLBI); U54TR001012 from
45 the National Centers for Advancing Translational Sciences; and U19AI168643 from the NIAID. GACRS
46 & VDAART metabolomic profiling and additional analyses were supported by R01HL123915,
47 R01HL141826, and R01HL155742. The Peanut Oral Immunotherapy (PNOIT) study clinical trial work
48 was performed at the Harvard Clinical and Translational Science Center supported by Grant Numbers
49 1UL1TR001102, 8UL1TR000170 from the National Center for Advancing Translational Science, and
50 1UL1 RR025758 from the National Center for Research Resources. PNOIT metabolomics profiling was
51 supported by the 2014 ARTrust Minigrant. This work is also supported by NIH NIAID (grant K23-
52 AI130408 for YVV, T32AI007062 for JNS, 1R01AI155630 for SUP), and NHLBI (K01 HL146980 for
53 RSK). CEW was supported by the Swedish Heart-Lung Foundation (HLF 20230463, HLF 20210519).
54 SB is supported by the NIH NIAID (UM1 AI173380, U19 AI136053, R01 AI147028, U01 AI160082). EB
55 is supported by NIEHS (P42ES027704) and NIGMS (R01GM141277 and RM1GM145416).

56 **ORCID:**

57 Yamini V. Virkud,^{1,2,3,4} (<https://orcid.org/0000-0001-7328-7215>)
58 Jennifer N. Styles¹, (<https://orcid.org/0000-0001-6777-1334>)
59 Rachel S. Kelly,^{3,4} , (<https://orcid.org/0000-0003-3023-1822>)
60 Sarita U. Patil^{2,3,5}, (<https://orcid.org/0000-0002-2172-2286>)
61 Bert Ruiter^{2,3}, (<https://orcid.org/0000-0003-3945-3202>)
62 Neal P. Smith², (<https://orcid.org/0000-0003-1394-3158>)
63 Clary Clish,⁵ (<https://orcid.org/0000-0001-8259-9245>)
64 Craig E. Wheelock,⁶ (<https://orcid.org/0000-0002-8113-0653>)
65 Juan C. Celedón,⁷ (<https://orcid.org/0000-0002-6139-5320>)
66 Augusto A. Litonjua,^{3,4} (<https://orcid.org/0000-0003-0422-5875>)
67 Supinda Bunyavanich,⁸ (<https://orcid.org/0000-0001-6108-439X>)
68 Scott T. Weiss,^{3,4} (<https://orcid.org/0000-0001-7196-303X>)
69 Erin S. Baker,⁹ (<https://orcid.org/0000-0001-5246-2213>)
70 Jessica A. Lasky-Su*,^{3,4} (<https://orcid.org/0000-0001-6236-4705>)
71 Wayne G. Shreffler*^{2,3,5} (<https://orcid.org/0000-0001-6465-137X>)

72 **Abstract:**

73 *Background:* The immunometabolic mechanisms underlying variable responses to oral immunotherapy
74 (OIT) in patients with IgE-mediated food allergy are unknown.

75 *Objective:* To identify novel pathways associated with tolerance in food allergy, we used metabolomic
76 profiling to find pathways important for food allergy in multi-ethnic cohorts and responses to OIT.

77 *Methods:* Untargeted plasma metabolomics data were generated from the VDAART healthy infant
78 cohort (N=384), a Costa Rican cohort of children with asthma (N=1040), and a peanut OIT trial (N=20)
79 evaluating sustained unresponsiveness (SU, protection that lasts after therapy) versus transient
80 desensitization (TD, protection that ends immediately afterwards). Generalized linear regression
81 modeling and pathway enrichment analysis identified metabolites associated with food allergy and OIT
82 outcomes.

83 *Results:* Compared with unaffected children, those with food allergy were more likely to have
84 metabolomic profiles with altered histidines and increased bile acids. Eicosanoids (e.g., arachidonic
85 acid derivatives) ($q=2.4 \times 10^{-20}$) and linoleic acid derivatives ($q=3.8 \times 10^{-5}$) pathways decreased over time
86 on OIT. Comparing SU versus TD revealed differing concentrations of bile acids ($q=4.1 \times 10^{-8}$),
87 eicosanoids ($q=7.9 \times 10^{-7}$), and histidine pathways ($q=0.015$). In particular, the bile acid lithocholate
88 ($4.97[1.93, 16.14]$, $p=0.0027$), the eicosanoid leukotriene B4 ($3.21[1.38, 8.38]$, $p=0.01$), and the histidine
89 metabolite urocanic acid ($22.13[3.98, 194.67]$, $p=0.0015$) were higher in SU.

90 *Conclusions:* We observed distinct profiles of bile acids, histidines, and eicosanoids that vary among
91 patients with food allergy, over time on OIT and between SU and TD. Participants with SU had higher
92 levels of metabolites such as lithocholate and urocanic acid, which have immunomodulatory roles in
93 key T-cell subsets, suggesting potential mechanisms of tolerance in immunotherapy.

94 **Key Messages**

- 95 - Compared with unaffected controls, children with food allergy demonstrated higher levels of bile
96 acids and distinct histidine/urocanic acid profiles, suggesting a potential role of these
97 metabolites in food allergy.
- 98 - In participants receiving oral immunotherapy for food allergy, those who were able to maintain
99 tolerance -even after stopping therapy- had lower overall levels of bile acid and histidine
100 metabolites, with the exception of lithocholic acid and urocanic acid, two metabolites that have
101 roles in T cell differentiation that may increase the likelihood of remission in immunotherapy.


102 **Capsule summary**

103 This is the first study of plasma metabolomic profiles of responses to OIT in individuals with IgE-
104 mediated food allergy. Identification of immunomodulatory metabolites in allergic tolerance may help
105 identify mechanisms of tolerance and guide future therapeutic development.

106 **Key Words:**

107 Food Allergy, Immunotherapy, IgE-mediated food allergy, Metabolomics, Secondary bile acids
 108 Lithocholic acid, Lithocholate, Eicosanoids, Arachidonic acid, Bile acids, Urocanic acid, Histidines;
 109 Sustained Unresponsiveness; Transient Desensitization; Remission

110 **Graphical Abstract:**



112 **Introduction:**


113 The prevalence of potentially life-threatening immunoglobulin E (IgE)-mediated food allergies is
114 currently estimated at 8-10%, and as the prevalence continues to rise, the need for treatment options
115 becomes more urgent.¹⁻³ The development of novel therapies requires a comprehensive understanding
116 of immune tolerance to allergens, including how tolerance differs between individuals with and without
117 food allergies, and how this is modified by treatment.

118
119 Although oral immunotherapy (OIT) was approved as the first and only treatment for IgE-mediated
120 peanut allergies in 2020, the effects of such treatment can have limited duration and lead to allergic
121 adverse events.⁴ Most individuals with food allergy (~50-75%) are capable of achieving transient
122 desensitization, a state where daily OIT protects against accidental exposure to allergen by increasing
123 the eliciting dose for a reaction. While estimates vary by study, only approximately one-third of children
124 demonstrate sustained unresponsiveness (also described as remission), a state of clinical tolerance to
125 large doses of allergen persisting at least weeks after cessation of regular allergen consumption.^{5, 6}
126 Studies of patients on OIT therefore provide a unique insight into the pathophysiology of allergen-
127 specific immunity. Furthermore, while the adaptive immunity underlying food allergies and therapeutic
128 responses have been studied extensively, little is known about the immunometabolism (the interaction
129 between immunity and metabolism) of the modification of tolerance to food allergens.⁷⁻⁹

130
131 Metabolomics, defined as study of small molecule cellular substrates, intermediates and products of
132 cellular metabolism, can be used to gauge the physiologic state of an organism and can reflect the
133 interaction of the genome, transcriptome, proteome, microbiome, and environmental influences on
134 disease.^{10, 11} Studies support the utility of metabolomic analyses in identifying pathways associated with
135 food allergy, while several investigations have explored the evolution of metabolomic profiles on other
136 types of aeroallergen sublingual and subcutaneous immunotherapy.^{9, 12-21} To date, one study has
137 examined water soluble metabolites in the stool in the setting of food immunotherapy, and none have
138 studied the plasma metabolome in humans.²²

139
140 Our main objectives were to (1) examine metabolomic profiles of individuals with food allergy in multi-
141 ethnic cohorts (Genetics of Asthma in Costa Rica (GACRS) and the Vitamin D Antenatal Asthma
142 Reduction Trial (VDAART) infant cohort) to identify key pathways of interest, (2) explore how those and
143 other metabolomic pathways evolve with OIT (using the Peanut Oral Immunotherapy trial (PNOIT)),
144 and (3) associate the metabolomic profiles with therapeutic OIT outcomes (**Figure 1**). We used
145 longitudinal sampling to define pathophysiologic differences between those who develop transient
146 desensitization versus sustained unresponsiveness while on OIT, to reveal novel mechanisms in
147 immune tolerance and inform future adjunctive therapies that may shift the response to OIT towards
148 longer-lasting protection.

149



150
151 **Figure 1: Overview of Cohort Study Design and Analysis in 3 studies.** Top: To study the metabolomics of food allergy, 2
152 cohorts, the Genetics of Asthma in Costa Rica (GACRS) and the Vitamin D Antenatal Asthma Reduction Trial (VDAART) were
153 used. Food allergy status was determined based on available clinical data (self-report for GACRS and detailed food allergy
154 questionnaire for VDAART). Untargeted metabolomic profiles were compared between participants with food allergy and
155 unaffected controls to identify key metabolites and subclasses of interest. Bottom: To study the metabolomics of OIT responses,
156 we used the Peanut Oral Immunotherapy trial (PNOIT), where participants underwent 56 weeks of peanut immunotherapy,
157 followed by 4 weeks of avoidance to determine who could maintain the protection of OIT after stopping (sustained
158 unresponsiveness, SU) versus who lost protection soon after stopping (transient desensitization, TD), as determined by oral
159 food challenges to full servings of peanut. Untargeted metabolomics was performed on the SU and TD groups to determine
160 metabolites that changed over time on OIT versus those that differed between SU and TD groups. Created with BioRender.com.

161
162 **METHODS:**

163 **Study Populations:**

164 Metabolomics data from three populations was compiled to address our objectives: (1) the Genetics of
165 Asthma in Costa Rica Study (GACRS),²³⁻²⁶ (2) the Vitamin D Antenatal Asthma Reduction Trial
166 (VDAART),²⁷ and (3) the Peanut Oral Immunotherapy (PNOIT) trial.²⁸

167
168 **GACRS:** Participants in the GACRS are members of a semi-isolated Latin American population from
169 the Central Valley of Costa Rica, which has one of the highest rates of asthma worldwide (24% in
170 children).²³⁻²⁵ Children ages 6-14 years were eligible for the study if they had asthma (physician-

171 diagnosed asthma and ≥ 2 respiratory symptoms or asthma attacks in the prior year) and a high
172 probability of having ≥ 6 great-grandparents born in the Central Valley of Costa Rica. A total of 1,189
173 children with asthma and their parents (i.e., 383 parent-child trios) were enrolled. The parents of
174 participating children completed extensive questionnaires, including a slightly modified and translated
175 version of the questionnaire used in the Collaborative Study on the Genetics of Asthma²⁹. Metabolomic
176 profiling was available for 1159 participants, and of those food allergy data were available for 1040
177 participants.

178 *VDAART*: The pediatric cohort of *VDAART* comprises the infants of mothers who were prenatally
179 randomized to Vitamin D supplementation versus placebo in the multi-center trial (ClinicalTrials.gov ID
180 NCT00920621).²⁷ All infants had a family history of asthma, eczema or allergic rhinitis in at least one
181 biological parent. Families completed comprehensive questionnaires with detailed phenotyping of
182 allergic diseases, including food allergy. The original study enrolled 881 mothers and their infants. We
183 used metabolomic data (available for 411 participants) from plasma samples collected at age 3, to
184 study the association with food allergy at that age (available for 384 participants).

185 *PNOIT*: Pediatric participants (aged 7-21) enrolled in an open-label interventional peanut OIT trial,
186 which involved the administration of gradually increasing doses of peanut allergen in order to decrease
187 patients' sensitivity to peanut allergen (ClinicalTrials.gov ID NCT01324401).²⁸ Participants underwent a
188 buildup phase where they were given incrementally increasing amounts of peanut protein, followed by a
189 maintenance period with a daily dose of 4 grams. After 12 weeks of maintenance, participants
190 underwent an oral food challenge (OFC1), followed by 1 month of peanut avoidance. A final double-
191 blind, placebo controlled food challenge (OFC2) was performed to assess transient desensitization
192 (those who failed OFC2) versus sustained unresponsiveness (those who passed OFC2). Blood
193 sampling for metabolome datasets occurred at baseline, early build-up (at the peak of AEs), OFC1, and
194 final OFC2 and was conducted for those with sufficient sample who developed transient desensitization
195 or sustained unresponsiveness (n=20).

196 For all three cohorts, written parental consent on behalf of the child and child's assent, if age
197 appropriate, were obtained. All three studies were approved by the trial sites Institutional Review
198 Boards. Further study design details are available in the original publications for each of the studies.²⁶⁻²⁸
199

200 **Food Allergy Case identification**

201 *GACRS*: The parents of study participants were asked by questionnaire if their child experienced a
202 food allergy and to which food, and we defined cases as parental report of an allergy to one of the 8
203 most common food allergens (milk, soy, egg, wheat, fish, shellfish, peanuts, tree nuts). Unaffected
204 controls were those whose parents did not report food allergy. Participants with a report of a food
205 allergy to an atypical allergen were excluded.

206 *VDAART*: Participants were given a detailed food allergy questionnaire which included questions
207 about suspected food allergies, symptoms associated with reactions, positive testing by skin test or
208 serum IgE test, and prescription with an epinephrine auto-injector. Some patients also had
209 corroborating specific IgE levels for foods. Patients with a convincing history (report allergen triggering
210 hives, swelling, cough, wheeze, vomiting, diarrhea) and evidence of sensitization (by positive blood IgE
211 or reported positive skin or blood testing) were reviewed by an allergist and included as cases.
212 Unaffected controls were those who did not report food allergy, and anyone reporting a food allergy but
213 not meeting criteria for diagnosis was excluded.

214 *PNOIT*: Inclusion criteria included objective symptoms after peanut ingestion, and either a peanut-
215 specific IgE >10 kU/L or elevated peanut-specific skin prick test >8 mm. All patients demonstrated IgE-
216 mediated symptoms during the early dosing of OIT, confirming the presence of true IgE-mediated food
217 allergy.²⁸

218

219 **Untargeted Metabolomics**

220 Plasma samples were collected from all three populations, and metabolomic profiling was performed
221 by the Clish laboratory at the Broad Institute for GACRS and PNOIT, and by Metabolon Inc for
222 VDAART. Liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) methods were
223 used to examine 4 classes of metabolites: 1) hydrophilic interaction liquid chromatography (HILIC)-
224 MS/MS in positive ion mode (e.g., amino acids); (2) HILIC-MS/MS in negative ion mode (e.g., cAMP);
225 (3) C8 reversed phase LC-MS/MS for lipids (e.g., steroids), and (4) C18 reversed phase LC-MS/MS for
226 free fatty acids, (e.g., bile acids and eicosanoids). Features were indexed by their mass-to-charge ratio
227 and LC retention time and metabolite identities were confirmed using known standards.^{30, 31} All features
228 were log transformed to normalization and *pareto*-scaled to reduce the variation in fold change
229 differences between the features. To ensure uniform classification of metabolite subclasses between
230 the three cohorts, the Relational Database of Metabolic Pathways (RaMP) was used to identify the
231 chemical subclass of each metabolite based on The Human Metabolome Database identifiers (HMDB
232 v.5.0).^{32, 33}

233

234 **Statistical Analysis**

235 Comparisons of demographics were conducted using chi-square or Fisher's exact tests, between
236 individuals with food allergy and unaffected controls, and also between patients with sustained
237 unresponsiveness versus transient desensitization. For GACRS and VDAART, we constructed
238 generalized linear models for each cohort separately to assess the association of metabolites with
239 reported food allergy, with adjustment for sex, age at blood collection, and for VDAART, race (Black,
240 White, Asian, Other). For PNOIT, we used generalized linear regression (GLM) modeling, with
241 adjustment for age, to identify significant metabolites, with linear regression to determine metabolites
242 varying with time on OIT (from baseline to post-OIT), and logistic regression to identify metabolites
243 associated with outcome (transient desensitization versus sustained unresponsiveness), adjusted for
244 time on OIT from baseline to post-OIT. To summarize findings in PNOIT, we defined a set of key
245 pathways of interest based on biological significance in atopic disease (polyunsaturated fatty acids,
246 which include arachidonic acid metabolites, and sphingolipids), and based on top metabolite
247 subclasses that were altered in the setting of food allergy compared to unaffected controls from
248 VDAART & GACRS. The full set of findings are included in the corresponding supplemental figures for
249 each set of analyses. Pathway analysis was performed using both chemical enrichment analysis
250 (reported from the metabolite subclass) and biological pathway enrichment (based on biological
251 pathways from KEGG from HMDB v5.0, Reactome v85, and WikiPathways v20230710) using the
252 RaMP v2.3.0 (RaMP-DB R package).^{32, 34-36} All subclasses were defined using ClassyFire structural
253 classification, from HMDB v5.0.^{34, 37} To capture the full range of potentially relevant subclasses and
254 pathways, individual metabolites were reported based on a nominal significance of $p < 0.05$, while
255 chemical subclasses and biological pathways were reported using FDR corrected significance of
256 $p < 0.05$. All analyses were performed using R 4.2.2.³⁸ Metabolomic data are available through the
257 dbGaP for GACRS, the ECHO consortium for VDAART, and Metabolomics Workbench for PNOIT.³⁹⁻⁴¹

258

259 **RESULTS:**

260 **Population demographics of three studies: two observational cohorts, GACRS and VDAART,**
 261 **and the PNOIT interventional trial**

262 We used 2 observational cohorts, GACRS (n=1040 children with asthma) and VDAART (n=384 healthy
 263 infants) to study the metabolomics of food allergy. The prevalence of reported food allergy in GACRS
 264 was 5% (57/1040), while the prevalence of reported, validated, food allergy in VDAART was 6%
 265 (22/384) (**Table 1**). Both populations were approximately 40% female; differences in racial/ethnicity
 266 demographics were consistent with those between the countries of each study. Regarding atopic
 267 disease, the GACRS cohort had higher proportions of allergic rhinitis, whereas, the VDAART cohort
 268 had higher percentages of eczema, consistent with the older versus younger ages of each cohort.
 269 Approximately a quarter of the VDAART cohort experienced asthma/persistent wheeze by age 3,
 270 compared with all reporting asthma symptoms in GACRS due to study design.

271 From the original PNOIT trial cohort,²⁸ 30 participants were enrolled, 27 completed treatment, and 13
 272 participants developed transient desensitization (TD) compared to 9 with sustained unresponsiveness
 273 (SU), and 5 participants experienced treatment failure. Metabolomic profiling was performed on 11 of
 274 13 participants found to have transient desensitization (TD) and all 9 participants with sustained
 275 unresponsiveness (SU); 2 samples from participants who developed TD were not included in
 276 metabolomic profiling due to inadequate sample volumes. All participants in the PNOIT interventional
 277 trial had IgE-mediated food allergy by study design, and rates of asthma and allergic rhinitis were
 278 similar to those seen in the food-allergic population of VDAART (**Table 1**).

Genetics of Asthma in Costa Rica Study (GACRS)				
	Overall N=1040	Food Allergic (n=57)	Unaffected Controls (n=983)	p-value
Male (%)	619 (60%)	28 (49%)	591 (60%)	0.13
Age at Sampling (years)	9.2 (1.9)	9.0 (1.8)	9.3 (1.9)	0.39
Hispanic/Latinx	1040 (100%)	57 (100%)	983 (100%)	1.00
Physician Diagnosed				
Asthma	1012 (97%)	55 (97%)	957 (97%)	1.00
Allergic Rhinitis	335 (32%)	24 (42%)	311 (32%)	0.14
Eczema	45 (4%)	6 (11%)	39 (4%)	0.04
Vitamin D Antenatal Asthma Reduction Trial (VDAART)				
	Overall N=384	Food Allergic (n=22)	Unaffected Controls (n=362)	p-value
Male (%)	207 (54%)	12 (55%)	195 (54%)	1.00
Age at Sampling (years)	3.0 (0.09)	3.0 (0.1)	3.0 (0.09)	0.30
Race				0.11
Black	186 (48%)	16 (73%)	170 (47%)	
White	125 (33%)	4 (18%)	121 (33%)	
Asian	22 (6%)	0 (0%)	22 (6%)	

Other	51 (13%)	2 (9%)	49 (14%)	
Hispanic/Latinx	126 (33%)	7 (32%)	119 (33%)	1.00
Reported Asthma/ Wheeze by age 3	100 (26%)	15 (68%)	85 (24%)	<0.001
Physician Diagnosed				
Asthma	53 (14%)	12 (55%)	41 (11%)	<0.001
Allergic Rhinitis	72 (19%)	11 (50%)	61 (17%)	<0.001
Eczema	184 (48%)	22 (100%)	162 (45%)	<0.001
Peanut Oral Immunotherapy Trial (PNOIT)				
	Overall N=20	Sustained Unresponsiveness (SU) (n=9)	Transient Desensitization (TD) (n=11)	p-value
Male (%)	15 (75%)	7 (78%)	8 (73%)	1.00
Mean Age at Enrollment (years (SD))	9.9 (2.1)	9.8 (2.3)	10.0 (2.1)	0.81
Race				0.40
Asian	2 (10%)	1 (11%)	1 (9%)	
White	16 (80%)	8 (89%)	8 (73%)	
Other	2 (10%)	0 (0%)	2 (18%)	
Hispanic/Latinx	1 (5%)	0 (0%)	1 (9%)	1.00
Allergic comorbidities				
Asthma	8 (40%)	3 (33%)	5 (45%)	0.93
Allergic Rhinitis	12 (60%)	7 (78%)	5 (45%)	0.31
Eczema	11 (55%)	3 (33%)	8 (73%)	0.19

279 **Table 1: Demographics of GACRS, VDAART, and PNOIT studies.** For GACRS, race was not collected from the Costa
280 Rican population.

281 **Food allergy in GACRS and VDAART associated with alterations in bile acid and histidine**
282 **metabolism**

283 After quality control measures, 595 named metabolites in GACRS and 655 in VDAART were available
284 for analysis. Regression analysis revealed that 16 (3%) metabolites in GACRS and 17 (3%)
285 metabolites in VDAART were associated with food allergy (**Figure 2**). Among these metabolites, the
286 most common subclasses included amino acids (11 metabolites) and bile acids (8 metabolites). Within
287 the amino acid pathway, histidine metabolism was the most prominent, with 2 metabolites increased
288 among individuals with food allergy individuals (N-acetyl histidine and urocanic acid, (range of odds
289 ratios (OR) 1.70-4.08, and range of p-values 0.017-0.018), and one metabolite, ergothioneine (OR
290 0.17, p=0.023) increased in unaffected controls. Among bile acids, metabolites included both primary
291 and secondary bile acids, and all 8 were increased in those with food allergy (range of OR: 1.13-3.44,
292 range of p-values: 0.0002-0.04). Based on these findings, we included bile acids and histidine
293 metabolites in our list of curated pathways to study in OIT.




295 **Figure 2: Metabolomic profiling of Food Allergy in the GACRS and VDAART pediatric populations identifies altered**
296 **bile acid and histidine metabolic pathways.** Plasma metabolites associated with food allergy using logistic regression
297 within each cohort, adjusted for age, sex, and race (for VDAART only), identified 29 significant metabolites higher in
298 participants with food allergy (orange) and 9 significant metabolites higher in unaffected controls (yellow). Pathways with 3 or
299 more unique metabolites included bile acids and histidine metabolism. Metabolomic profiling for each cohort was conducted in
300 different laboratories, leading to some differences in annotation of metabolites.

301 **Polyunsaturated fatty Acids (PUFAs), including arachidonic acid derivatives, decrease over time** 302 **on OIT in all participants (PNOIT)**

303 After quality control measures, 529 named metabolites were available for analysis in the PNOIT cohort.
304 Analyzing metabolite trajectories over time, metabolites showed longitudinal differences associated with
305 OIT among all participants (**Figure E1**). Subclasses with the highest number of significant metabolites
306 included eicosanoids (17 significant metabolites decreased over time), glycerophosphocholines (14
307 significant metabolites increased and 2 decreased over time), and glycerophosphoethanolamines (9
308 significant metabolites increased and 1 decreased over time) (**Figure 3a**). Several subclasses were
309 notable in that all significant metabolites (and a majority of non-significant metabolites) in that class
310 changed in the same direction, including increasing triacylglycerols, decreasing linoleic acids, and
311 decreasing eicosanoids over time on OIT. Chemical subclass pathway enrichment of the significant
312 metabolites identified top subclasses including eicosanoids, ($q=2.4 \times 10^{-20}$, enrichment ratio=43),
313 glycerophosphocholines ($q=1.4 \times 10^{-13}$, enrichment ratio=15), and steroid esters ($q=3.7 \times 10^{-6}$, enrichment
314 ratio=33) (**Figure 3b**). Biological pathway enrichment analysis also identified a number of
315 PUFA/eicosanoid related pathways, including arachidonic acid oxylipin metabolism ($q=7.6 \times 10^{-5}$, 13% of
316 metabolites in pathway), metabolism of alpha-linolenic acid ($q=1.1 \times 10^{-5}$, 35% of pathway), eicosanoid
317 metabolism via lipoxygenases (LOX) ($q=0.00072$, 19% of pathway), and eicosanoid synthesis
318 ($q=0.02$, 15% of metabolites in pathway). Additionally, amino acids: histidine catabolism ($q=4.0 \times 10^{-5}$,
319 35% of pathway), and sphingolipid metabolism ($q=0.025$, 21% of pathway) were also identified by
320 biological pathway enrichment.

321 Based on biological significance in other atopic diseases and key metabolites associated with food
322 allergy in GACRS and VDAART, we defined a set of key pathways of interest, including histidine
323 metabolism, bile acids, sphingolipids, and polyunsaturated fatty acids (PUFAs) including linoleic acid
324 derivatives and eicosanoids (**Figure 3d**, all significant metabolites in **Figure E1b**). Of note, bile acids
325 were not detected in association with asthma in the VDAART cohort. Among PUFAs, significant
326 decreases in all participants during OIT were detected among the eicosanoids, including leukotriene B3
327 and B4, lipoxin A4, and several HETEs/DiHETES (range of coefficients: -0.04 to -0.071, range of p
328 values: 1.9×10^{-7} to 0.0014). All linoleic acid derivatives, including linoleic acid, 13-HpODE, and 13-
329 HODE decreased (range of coefficients: -0.062 to -0.015, range of p-values: 5.7×10^{-07} to 0.035) and all
330 detected sphingolipids increased over time on OIT (range of coefficients: 0.027 to 0.031, range of p
331 values: 0.017 to 0.036). No bile acid or main histidine pathway metabolites were identified as changing
332 over time on OIT.

333






334 **Figure 3 – PNOIT: Metabolites associated with change over time in the entire cohort during OIT.** (A) Subclasses of
 335 significant ($p < 0.05$) metabolites with the number of metabolites increasing (purple) and decreasing (green). The total number
 336 of detected non-significant metabolites within each subclass is denoted in gray. Pathway enrichment analyses show (B)

337 enrichment ratios (ratio of observed significant metabolites divided by expected significant metabolites) of chemical subclasses
338 plotted by the FDR adjusted p-value plotted on a log₁₀ scale, and (C) percent of significant metabolites divided by the total
339 metabolites within the pathway plotted by the FDR-adjusted p-value plotted on a log₁₀ scale. In B & C, black line denotes
340 $q < 0.05$, and key pathways of interest are labeled in magenta (bile acids, eicosanoids, linoleic acids, sphingolipids, histidine
341 metabolites). (D) Association of each metabolite with time on OIT.

342 **Enrichment of bile acid, histidine, and eicosanoid pathways in sustained unresponsiveness in** 343 **PNOIT**

344 Adjusting for time, 116 named metabolites (21.9% of total named metabolites) differed between
345 individuals on OIT with sustained unresponsiveness compared to transient desensitization (**Figure**
346 **E2a**). Top subclasses, based on number of metabolites observed, included glycerophosphocholines (8
347 higher in SU and 10 higher in TD, $q = 6.8 \times 10^{-16}$; enrichment ratio=18) and amino acids, peptides, and
348 analogues (12 higher in SU and 2 higher in TD, $q = 7.9 \times 10^{-7}$; enrichment ratio=6) (**Figure 4a**).
349 Subclasses that were notable because all significant metabolites (and a majority of non-significant
350 metabolites) in that class were higher in one group included all triacylglycerols higher in transient
351 desensitization (6 metabolites), and all eicosanoid metabolites (8 metabolites) higher in sustained
352 unresponsiveness. Chemical enrichment analysis identified differences in bile acid ($q = 4.1 \times 10^{-8}$;
353 enrichment ratio=33) and eicosanoid ($q = 7.9 \times 10^{-7}$; enrichment ratio=19) subclasses between the two
354 groups (**Figure 4b**), and biological pathway enrichment (**Figure 4c**) showed significant enrichment of
355 several bile acid pathways, including recycling of bile acids and salts ($q = 2.0 \times 10^{-7}$; 45% of pathway),
356 transport of bile salts ($q = 5.4 \times 10^{-5}$; 15% of pathway), synthesis of bile acids and bile salts ($q = 0.00019$;
357 18% of pathway), and primary bile acid synthesis ($q = 0.017$; 17% of pathway), as well as, eicosanoid
358 metabolism via lipooxygenases (LOX) ($q = 0.030$; 9% of pathway), histidine catabolism ($q = 0.015$; 14%
359 of pathway), and sphingolipid metabolism ($q = 0.004$; 9% of pathway). Among the curated set of
360 pathways of interest, histidines (1 higher in SU, 1 with TD), bile acids (2 higher in SU and 5 with TD),
361 eicosanoids (8 higher in SU), and linoleic acid metabolites (1 higher in TD) all contained metabolites
362 significantly associated with clinical outcome (**Figure 4d** & all significant metabolites in **Figure E2b**).



D

Metabolites	OR [95% CI]	p-value (GLM)
Eicosanoids		
5,6 DHET	10.83 [2.52, 65.61]	0.0039
5-HETE	3.74 [1.43, 11.34]	0.012
14,15 diHETE	3.24 [1.38, 8.51]	0.01
LTB4	3.21 [1.38, 8.38]	0.01
17,18 diHETE	3.13 [1.31, 8.48]	0.015
Lipoxin A4	3.11 [1.23, 8.77]	0.022
LTB3	2.87 [1.26, 7.14]	0.016
5-HEPE	2.8 [1.25, 7.7]	0.024
Bile acids, alcohols and derivatives		
Lithocholate	4.97 [1.93, 16.14]	0.0027
Glycolithocholate	2.89 [1.16, 8.5]	0.034
Taurohyodeoxycholate_tauroursodeoxycholate	0.36 [0.13, 0.86]	0.029
Glycoursodeoxycholate	0.35 [0.12, 0.92]	0.044
Hyodeoxycholate_ursodeoxycholate	0.32 [0.1, 0.89]	0.037
Ketodeoxycholate	0.28 [0.1, 0.68]	0.0099
Alpha-muricholate	0.12 [0.03, 0.36]	0.00068
Amino acids (histidine metabolism)		
Urocanic acid	22.13 [3.98, 194.67]	0.0015
1-methylhistidine	0.2 [0.04, 0.85]	0.039
Linoleic acids and derivatives		
13-HODE	3.12 [1.15, 9.44]	0.033
Sphingolipids		
C24-1 SM	0.08 [0.01, 0.65]	0.027

364 **Figure 4 – PNOIT: Metabolites differing between participants who develop sustained**
365 **unresponsiveness (SU) compared to transient desensitization (TD).** (A) Subclasses of significant ($p < 0.05$)
366 metabolites with the number of metabolites higher in either SU (blue) or TD (red). The total number of detected non-significant
367 metabolites within each subclass is denoted in gray. Pathway enrichment analyses show (B) the ratio of observed significant
368 metabolites divided by the number of expected metabolites within the chemical subclass plotted by the FDR-adjusted p-value
369 plotted on a log₁₀ scale, and (C) the percent of significant metabolites divided by the total metabolites within the biological
370 pathway plotted by the FDR-adjusted p-value plotted on a log₁₀ scale. In B & C, black line denotes $q < 0.05$, and key pathways
371 of interest are labeled in magenta (bile acids, eicosanoids, linoleic acids, sphingolipids, histidine metabolites). (D) Association
372 of each metabolite with time on OIT.
373

374 Among bile acids, most were higher in transient desensitization (range of OR: 0.12-0.36, range of
375 $p = 0.00068-0.044$), with two in particular higher in sustained unresponsiveness, lithocholate (OR: 4.97,
376 $p = 0.0027$) and glycolithocholate (OR: 2.89, $p = 0.034$) (**Figure 4b**). For some metabolites,
377 ursodeoxycholate, alpha-muricholate, and ketodeoxycholate, trajectories differed at baseline, with
378 higher levels among transiently desensitized individuals, and converged over time on OIT (**Figure 5a**).
379 For lithocholate, levels stayed relatively stable during OIT, with higher concentrations among
380 participants with sustained unresponsiveness, whereas the downstream metabolite glycolithocholate
381 demonstrated converging trajectories during OIT.


382 Among PUFAs, significant metabolites were detected from the eicosanoid subclass, including
383 leukotriene B₃ (LTB₃) and LTB₄, lipoxin A₄ (LXA₄), 5,6-DHET (5,6-DiHETrE), and several
384 HETEs/DiHETES (range of OR: 2.80-10.83, range of p : 0.0039-0.024) (**Figure 4b**). With the exception
385 of 5,6-DiHETrE/5,6-DHET, all eicosanoid metabolites decreased over time on OIT, with more dramatic
386 decreases among those participants with transient desensitization than with sustained
387 unresponsiveness (**Figure 5b**).

388 For histidine metabolism, the 1-methylhistidine was higher in subjects with transient desensitization
389 (OR: 0.20, $p = 0.039$), whereas urocanic acid (OR: 22.13, $p = 0.0015$), was higher among participants with
390 sustained unresponsiveness (**Figure 4b**). The histidine derivatives demonstrated higher
391 concentrations at baseline and converged over time on therapy (**Figure 5c**). Meanwhile, urocanic acid
392 levels were similar between both groups of participants at baseline, and then diverged during OIT, most
393 dramatically between baseline and buildup, with higher levels among participants with sustained
394 unresponsiveness.

395

396


A.



397


398

B.




399

400 C.



401
402 D.



403

404 **Figure 5 – PNOIT: Overview of key metabolic pathways of interest and metabolite trajectories during OIT, between**
405 **transient desensitization (TD, red) and sustained unresponsiveness (SU, blue).** A. Bile acid pathway. B. Histidine
406 Pathway. C. Omega 3 fatty acids (PUFAs). D. Omega 6 fatty acids (PUFAs). Metabolites associated with food allergy are
407 denoted in small boxes colored by orange (higher in food allergy) or yellow (higher in unaffected controls). Metabolites
408 associated with time on OIT in the entire cohort are denoted in small boxes in green (decreasing during OIT) or purple
409 (increasing during OIT). Modified derivatives of the main metabolite are listed under the main metabolite. Only metabolites that
410 significantly differ in association with food allergy and/or OIT are depicted, with major biosynthetic processes in thick arrows
411 and simpler metabolic modifications in thin arrows. Graphs are only displayed for metabolites that differed significantly
412 between SU & TD. Listed odds ratio and confidence interval (OR [95%CI]) statistics are derived from logistic regression
413 models analyzing the association of the metabolite with OIT outcome (SU versus TD), adjusted for age and time on OIT.

414 **DISCUSSION:**

415 In this analysis of data from three studies including an international cohort, we conducted untargeted
416 metabolomic profiling of two epidemiologic cohorts and one interventional clinical trial to identify
417 metabolites associated with IgE-mediated food allergy and clinical responses to PNOIT. To our
418 knowledge, this is the first study of metabolomics in the setting of food allergen immunotherapy in
419 humans. In this analysis, we discovered a number of key metabolites (including bile acids and histidine
420 metabolites) associated with parental report of food allergy in GACRS, as well as with IgE-mediated
421 food allergy in VDAART. In PNOIT, exploration of these pathways among participants with confirmed
422 IgE-mediated food allergy demonstrated that bile acids, eicosanoids, and histidine metabolites were
423 associated with differential responses to OIT, distinguishing individuals with transient desensitization to
424 OIT lasting only the duration of active treatment from those with sustained unresponsiveness with
425 protection lasting at least a month beyond the cessation of OIT.

426 **The immunomodulatory roles of bile acids in food allergy and OIT**

427 *Elevated bile acids in food allergy*

428 Our work showed significantly higher levels of bile acids among children with food allergy compared to
429 unaffected controls, replicating findings from another study of serum metabolomics in food allergy.¹⁴
430 These bile acids however, were not associated with other atopic diseases, such as asthma in the
431 VDAART cohort. Other work in VDAART has shown that stool from children with food allergy is notable
432 for lower levels of bile acids compared to both unaffected controls and sensitized children (those with
433 food specific antibodies but not food-allergy).^{13, 18} This work has been replicated in another study
434 showing not only lower bile acids in stool from children with food allergy compared to healthy controls,
435 but also lower levels of bile acids in children with persistent food allergy.⁴² Combined with our findings
436 that children with food allergy in VDAART had higher levels of bile acids in the plasma, this suggests
437 the increase in plasma bile acids is most likely due to increased bile acid reabsorption in food-allergy,
438 rather than increased overall metabolism of bile acids by gut microbiota. Increased bile acid absorption
439 has been implicated in the mechanism of liver diseases and type 2 diabetes mellitus, and increased
440 bile acid levels have been linked to increases in intestinal permeability, notable because IgE-mediated
441 food allergy is also marked by dysfunctions in intestinal permeability.^{43, 44}

442 *Lower bile acids & and higher lithocholate derivatives in sustained efficacy on OIT*

443 In addition to elevated levels in food allergy, our work shows generally higher levels of bile acids,
444 especially deoxycholate derivatives, among individuals who only develop transient desensitization on

445 OIT (potentially a more severe phenotype of food allergy) (**Figure 5a**). The exceptions to this pattern,
446 lithocholate & glycolithocholate are higher among children who later develop sustained
447 unresponsiveness after stopping therapy. Given lithocholate derivatives actively alter T cell
448 differentiation,^{45, 46} our data suggest that lithocholate is not only a biomarker but may actively increase
449 the likelihood of allergic remission. These bile acid profiles seem to be present even before the
450 initiation of OIT, and while some bile acid trajectories converge over time on OIT, others, like
451 lithocholate remain relatively stable.

452 *Immunomodulatory roles of lithocholate on the T cell subsets associated with OIT outcomes*

453 Recent findings have uncovered many novel roles for bile acids in immune regulation of T cells.⁴⁷ Bile
454 acids are synthesized from cholesterol in the liver, secreted into the intestine to help with digestion,
455 modified by gut bacteria into secondary bile acids and then reabsorbed.⁴⁸ In murine models, a screen of
456 primary and secondary bile acids discovered that two lithocholate metabolites blocked Th17
457 differentiation and function and enhanced Treg differentiation, stability, and function.^{45, 46} Colonization
458 of mice with human bacterial strains that produce certain lithocholate derivatives can suppress Th17
459 levels and increase the gut Treg population.^{46, 49} In human studies of OIT, decreases in peanut-specific
460 Th17 frequency have been observed between those who achieve desensitization compared to those
461 who fail treatment,¹⁵ as well as decreased overall Th17 frequency over time on OIT among older
462 children and teens.⁵⁰ While peripheral allergen-specific Treg frequencies do not differ by sustained
463 unresponsiveness outcomes in OIT,^{15, 51} mucosal allergen-specific Treg responses have not been
464 studied, and OIT has been shown to induce increased expansion of the overall Treg compartment in
465 patients who develop sustained unresponsiveness, compared to those who develop transient
466 desensitization.^{52, 53} We propose that bile acids, such as lithocholate derivatives, modulate T cell
467 percentages and function to increase the likelihood of remission in OIT. Overall, these findings may
468 reflect not only the microbial differences in individuals who develop longer lasting protection from OIT,
469 but also an active role for bile acids in mediating these immunopathogenic differences.

470 **Altered histidine metabolism in food allergy and OIT**

471 Our work demonstrated altered serum histidine metabolism in food allergy, with metabolites such as
472 urocanic acid (UCA) and histidine were increased in those with food allergy while ergothioneine was
473 increased among unaffected controls. Others have also found altered histidine metabolism associated
474 with food allergy and food allergy development in both the serum and stool.^{14, 20} Histidine is an essential
475 amino acid that can be converted into both inflammatory mediators (e.g. histamine) but also anti-
476 inflammatory derivatives such as the cis-form of urocanic acid (UCA). In the skin, peanut allergic
477 children had lower levels of cis-UCA compared to non-atopic controls, independent of their atopic
478 dermatitis.⁵⁴ Given these findings, the elevation of UCA in food allergic children in GACRS is
479 unexpected, but may reflect differences between the isomers or between the plasma and skin
480 metabolome.

481 These data also demonstrate a role for histidine metabolites in OIT responses. In particular urocanic
482 acid (UCA) levels are higher in individuals with sustained unresponsiveness in PNOIT, though that
483 difference was apparently induced by OIT (**Figure 5b**). UCA has a number of immunomodulatory
484 functions, including increasing IL-10 expression, decreasing IFN-gamma production by antigen specific
485 T cells, and increasing Treg percentages.^{55, 56} IL-10 producing cells (including T regs, CD4+ T cells,

486 and regulatory B cells) are important for the development of allergic tolerance.⁸ Furthermore, our data
487 revealed higher levels of succinic acid in our participants with transient desensitization (**Figure E2a,**
488 **Dicarboxylic Acids & Derivatives**), and succinic acid inhibits histidase, the enzyme that converts
489 histidine into urocanic acid.⁵⁷ Both succinic acid and urocanic acid creation and degradation are
490 affected by skin and gut microbial flora,^{57, 58} all of which supports another potential pathway by which
491 the microbiome interacts with the immune system to effect tolerance on immunotherapy. Given the
492 known bidirectional nature of microbial-immune cross-talk,^{59, 60} this may provide a potential explanation
493 for why changes in urocanic acid do not occur until after OIT is initiated. Additionally, UCA is a
494 breakdown product of filaggrin, a key epithelial barrier protein which is a risk factor for food allergy and
495 is decreased in atopic dermatitis and eosinophilic esophagitis (EoE) but normalizes after treatment of
496 EoE.⁶¹⁻⁶³ Given the links between EoE, tissue eosinophilia, and OIT, the increase in UCA in sustained
497 unresponsiveness may reflect changes in filaggrin expression during OIT.⁶⁴ Overall, the divergence in
498 UCA trajectories between sustained unresponsiveness and transient desensitization suggest that the
499 role of UCA, as an immunomodulatory metabolite or as a reflection of changes in the microbiome or
500 filaggrin, merits further study.

501 **Decreases in PUFAs during OIT**

502 PUFAs (often described as omega-3 and omega-6 fatty acids) encompass a variety of subclasses of
503 metabolites, including eicosanoids and linoleic acid derivatives. Of these groups, eicosanoids (which
504 include arachidonic acid derivatives) have a well described role in the pathophysiology of allergic
505 disease, with many having an allergic pro-inflammatory role, including leukotrienes, and
506 prostaglandins.⁶⁵ In our data, all measured eicosanoids and linoleic acid derivatives decreased over
507 time on OIT, and we hypothesize that the general decrease in these inflammatory mediators is a result
508 of reduced inflammatory circuits and successful treatment (**Figure 5c**). The finding that participants with
509 transient desensitization exhibited more dramatic decreases than those with sustained
510 unresponsiveness was unexpected. One potential explanation involves a key effector CD4 T cell
511 subset, referred to as pathogenic effector (peTh2)⁶⁶ or Th2A,⁶⁷ which has emerged as a likely regulator
512 of multiple allergic disease, including food allergy. These Th2A are notable for several features that
513 distinguish them from Th2-skewed T follicular helper cells (necessary for high-affinity IgE) and other
514 Th2 subsets, including production of IL-9, expression of the transcriptional regulator PPAR γ , and the
515 marked upregulation of a set of eicosanoid sensing and synthesizing genes.⁶⁸⁻⁷² We and others have
516 shown that Th2A are suppressed by OIT in both TD and SU.^{15, 51} Recent data from cellular analysis of
517 young toddlers undergoing OIT also demonstrated that Th2A cells were suppressed over time by OIT,
518 and suggests one reason a decrease may be more dramatic in TD versus SU.⁵¹ For the one subject
519 analyzed who achieved SU, there were few Th2A cells present at baseline.⁵¹ Another possibility is that
520 these trajectories represent a shift between the arms of the eicosanoid pathway, where patients who go
521 on to develop sustained unresponsiveness, have a more dramatic decrease in prostaglandin
522 production. Prostaglandins were not detected in the plasma from these samples, but this merits further
523 study in future trials, ideally by the analysis of urine metabolites.

524 **Limitations**

525 This analysis compares three remarkably disparate populations: a cohort from Costa Rica, a country
526 with high prevalence of allergic asthma, a healthy cohort of US infants born to pregnant mothers from

527 an interventional trial of Vitamin D supplementation during pregnancy, and finally, children with food
528 allergy treated with peanut OIT. These cohorts include ages ranging from toddlers to teenagers, and
529 children with varied allergic comorbidities. The diagnosis of IgE-mediated food allergy in these cohorts
530 was of variable stringency, with the PNOIT cohort having the most reliable diagnosis (confirmed by
531 clinician observed reactions to allergen), the VDAART population being most similar to a standard
532 clinical cohort of IgE-mediated food allergy (diagnosed based on a combination of sensitization and
533 history, but often missing confirmatory food challenges) and GACRS cohort being the loosest, relying
534 on parentally reported food allergy. This work also faces limitations in the small sample sizes of
535 participants with food allergy. Because samples were being processed in parallel for isolation of cells,
536 samples were not handled with strict temperature control required for ideal metabolomics processing
537 prior to freezing. This may have altered detection of certain metabolites. Furthermore, the
538 metabolomics profiling was conducted by two different groups, which is known to influence the
539 uniformity of metabolite detection, particularly notable in the replication of pathways between VDAART
540 and GACRS but not generally the exact metabolites. Despite these differences in study population and
541 metabolomics processing, we found replication of pathways between cohorts. Also our work supports
542 findings in the food allergy literature showing differential production of sphingolipids, tryptophan
543 metabolites, alanine metabolites, glycerophosphoinositols, and pyridine carboxylic acid derivatives
544 (also described as Vitamin B3 metabolites).^{14, 73} Furthermore, many of the pathways associated with
545 food allergy were differentially produced when comparing the two clinical responses to OIT, adding
546 robustness to the hypothesis that these metabolites represent an important part of the immune
547 pathogenesis of IgE-mediated food allergy.

548 **Conclusion**

549 In summary, we have identified key metabolite pathways associated with food allergy and differential
550 responses to OIT. Many of these metabolites, including bile acids, eicosanoids, and histidine/urocanic
551 acid, have active roles in modulating the same T cell subsets that are thought to mediate remission in
552 allergen immunotherapy. Further functional validation of these metabolic pathways in the context of
553 allergic tolerance may both help identify patients most likely to benefit from OIT and guide the
554 development of adjunctive therapies that can improve outcomes of allergen immunotherapy.

555

556 **References**

- 557 1. Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, Schleimer RP, Nadeau
558 KC. Prevalence and Severity of Food Allergies Among US Adults. *JAMA Netw Open*.
559 2019;2(1):e185630. Epub 2019/01/16. doi: 10.1001/jamanetworkopen.2018.5630. PubMed PMID:
560 30646188;
- 561 2. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, Nadeau KC. The Public
562 Health Impact of Parent-Reported Childhood Food Allergies in the United States. *Pediatrics*.
563 2018;142(6). Epub 2018/11/21. doi: 10.1542/peds.2018-1235. PubMed PMID: 30455345;
- 564 3. Branum AM, Lukacs SL. Food allergy among children in the United States. *Pediatrics*.
565 2009;124(6):1549-55. Epub 2009/11/18. doi: 10.1542/peds.2009-1210. PubMed PMID: 19917585;
- 566 4. Pepper AN, Assa'ad A, Blaiss M, Brown E, Chinthrajah S, Ciaccio C, Fasano MB, Gupta R,
567 Hong N, Lang D, Mahr T, Malawer E, Roach A, Shreffler W, Sicherer S, Vickers K, Vickery BP,
568 Wasserman R, Yates K, Casale TB. Consensus report from the Food Allergy Research & Education
569 (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. *J Allergy Clin Immunol*. 2020;146(2):244-9.
570 Epub 2020/06/09. doi: 10.1016/j.jaci.2020.05.027. PubMed PMID: 32505612;
- 571 5. Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. *J Allergy Clin Immunol*.
572 2011;127(3):558-73; quiz 74-5. Epub 2011/02/01. doi: 10.1016/j.jaci.2010.12.1098. PubMed PMID:
573 21277625;
- 574 6. Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD,
575 Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC. Sustained
576 outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind,
577 placebo-controlled, phase 2 study. *Lancet*. 2019;394(10207):1437-49. Epub 2019/09/17. doi:
578 10.1016/S0140-6736(19)31793-3. PubMed PMID: 31522849;
- 579 7. Kazmi W, Berin MC. Oral tolerance and oral immunotherapy for food allergy: Evidence for
580 common mechanisms? *Cell Immunol*. 2023;383:104650. Epub 2022/12/22. doi:
581 10.1016/j.cellimm.2022.104650. PubMed PMID: 36543052;
- 582 8. Barshow SM, Kulis MD, Burks AW, Kim EH. Mechanisms of oral immunotherapy. *Clin Exp*
583 *Allergy*. 2021;51(4):527-35. Epub 2021/01/09. doi: 10.1111/cea.13824. PubMed PMID: 33417257;
- 584 9. Sindher SB, Chin AR, Aghaeepour N, Prince L, Maecker H, Shaw GM, Stevenson DK, Nadeau
585 KC, Snyder M, Khatri P, Boyd SD, Winn VD, Angst MS, Chinthrajah RS. Advances and potential of
586 omics studies for understanding the development of food allergy. *Front Allergy*. 2023;4:1149008. Epub
587 2023/04/11. doi: 10.3389/falgy.2023.1149008. PubMed PMID: 37034151;
- 588 10. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and
589 the continuum of metabolism. *Nat Rev Drug Discov*. 2003;2(8):668-76. PubMed PMID: 12904817;
- 590 11. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle
591 KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, Oliver SG. A functional genomics strategy that
592 uses metabolome data to reveal the phenotype of silent mutations. *Nat Biotechnol*. 2001;19(1):45-50.
593 doi: 10.1038/83496. PubMed PMID: 11135551;
- 594 12. Kong J, Chalcraft K, Mandur TS, Jimenez-Saiz R, Walker TD, Goncharova S, Gordon ME, Naji
595 L, Flader K, Larche M, Chu DK, Wasserman S, McCarty B, Jordana M. Comprehensive metabolomics
596 identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. *Allergy*.
597 2015;70(5):495-505. doi: 10.1111/all.12579. PubMed PMID: 25647422;
- 598 13. Lee-Sarwar KA, Chen YC, Lasky-Su J, Kelly RS, Zeiger RS, O'Connor GT, Bacharier LB, Jia X,
599 Beigelman A, Gold DR, Laranjo N, Bunyavanich S, Weiss ST, Litonjua AA, Brennan PJ. Early-life fecal
600 metabolomics of food allergy. *Allergy*. 2023;78(2):512-21. Epub 2022/12/01. doi: 10.1111/all.15602.
601 PubMed PMID: 36448508;
- 602 14. Crestani E, Harb H, Charbonnier LM, Leirer J, Motsinger-Reif A, Rachid R, Phipatanakul W,
603 Kaddurah-Daouk R, Chatila TA. Untargeted metabolomic profiling identifies disease-specific signatures
604 in food allergy and asthma. *J Allergy Clin Immunol*. 2020;145(3):897-906. Epub 2019/11/02. doi:
605 10.1016/j.jaci.2019.10.014. PubMed PMID: 31669435;

- 606 15. Monian B, Tu AA, Ruiter B, Morgan DM, Petrossian PM, Smith NP, Gierahn TM, Ginder JH,
607 Shreffler WG, Love JC. Peanut oral immunotherapy differentially suppresses clonally distinct subsets of
608 T helper cells. *J Clin Invest.* 2022;132(2). Epub 2021/11/24. doi: 10.1172/JCI150634. PubMed PMID:
609 34813505;
- 610 16. Xie S, Jiang S, Zhang H, Wang F, Liu Y, She Y, Jing Q, Gao K, Fan R, Xie S, Xie Z, Jiang W.
611 Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis. *Int*
612 *Immunopharmacol.* 2021;90:107211. Epub 2020/12/04. doi: 10.1016/j.intimp.2020.107211. PubMed
613 PMID: 33271394;
- 614 17. Zheng P, Yan G, Zhang Y, Huang H, Luo W, Xue M, Li N, Wu JL, Sun B. Metabolomics Reveals
615 Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous
616 Immunotherapy. *Metabolites.* 2021;11(9). Epub 2021/09/27. doi: 10.3390/metabo11090613. PubMed
617 PMID: 34564431;
- 618 18. Lee-Sarwar K, Kelly RS, Lasky-Su J, Moody DB, Mola AR, Cheng TY, Comstock LE, Zeiger RS,
619 O'Connor GT, Sandel MT, Bacharier LB, Beigelman A, Laranjo N, Gold DR, Bunyavanich S, Savage
620 JH, Weiss ST, Brennan PJ, Litonjua AA. Intestinal microbial-derived sphingolipids are inversely
621 associated with childhood food allergy. *J Allergy Clin Immunol.* 2018;142(1):335-8 e9. Epub
622 2018/05/08. doi: 10.1016/j.jaci.2018.04.016. PubMed PMID: 29729303;
- 623 19. Savage JH, Lee-Sarwar KA, Sordillo J, Bunyavanich S, Zhou Y, O'Connor G, Sandel M,
624 Bacharier LB, Zeiger R, Sodergren E, Weinstock GM, Gold DR, Weiss ST, Litonjua AA. A prospective
625 microbiome-wide association study of food sensitization and food allergy in early childhood. *Allergy.*
626 2018;73(1):145-52. Epub 2017/06/21. doi: 10.1111/all.13232. PubMed PMID: 28632934;
- 627 20. Chun Y, Grishin A, Rose R, Zhao W, Arditi Z, Zhang L, Wood RA, Burks AW, Jones SM, Leung
628 DYM, Jones DR, Sampson HA, Sicherer SH, Bunyavanich S. Longitudinal dynamics of the gut
629 microbiome and metabolome in peanut allergy development. *J Allergy Clin Immunol.* 2023;152(6):1569-
630 80. Epub 2023/08/25. doi: 10.1016/j.jaci.2023.08.012. PubMed PMID: 37619819;
- 631 21. Bunyavanich S, Becker PM, Altman MC, Lasky-Su J, Ober C, Zengler K, Berdyshev E,
632 Bonneau R, Chatila T, Chatterjee N, Chung KF, Cutcliffe C, Davidson W, Dong G, Fang G, Fulkerson
633 P, Himes BE, Liang L, Mathias RA, Ogino S, Petrosino J, Price ND, Schadt E, Schofield J, Seibold MA,
634 Steen H, Wheatley L, Zhang H, Togias A, Hasegawa K. Analytical Challenges in Omics Research on
635 Asthma and Allergy: A National Institute of Allergy and Infectious Diseases Workshop. *J Allergy Clin*
636 *Immunol.* 2024. Epub 2024/02/01. doi: 10.1016/j.jaci.2024.01.014. PubMed PMID: 38295882;
- 637 22. Shibata R, Itoh N, Nakanishi Y, Kato T, Suda W, Nagao M, group JO, Iwata T, Yoshida H,
638 Hattori M, Fujisawa T, Shimojo N, Ohno H. Gut microbiota and fecal metabolites in sustained
639 unresponsiveness by oral immunotherapy in school-age children with cow's milk allergy. *Allergol Int.*
640 2024;73(1):126-36. Epub 2024/01/06. doi: 10.1016/j.alit.2023.10.001. PubMed PMID: 38182280;
- 641 23. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C, the IPTSG.
642 Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma
643 and Allergies in Childhood (ISAAC). *Thorax.* 2007;62(9):758-66. doi: 10.1136/thx.2006.070169.
644 PubMed PMID: PMC2117323;
- 645 24. Celedon JC, Soto-Quiros ME, Silverman EK, Hanson L, Weiss ST. Risk factors for childhood
646 asthma in Costa Rica. *Chest.* 2001;120(3):785-90. Epub 2001/09/14. doi: 10.1378/chest.120.3.785.
647 PubMed PMID: 11555510;
- 648 25. Hunninghake GM, Soto-Quiros ME, Avila L, Ly NP, Liang C, Sylvia JS, Klanderman BJ,
649 Silverman EK, Celedon JC. Sensitization to *Ascaris lumbricoides* and severity of childhood asthma in
650 Costa Rica. *J Allergy Clin Immunol.* 2007;119(3):654-61. Epub 2007/03/06. doi:
651 10.1016/j.jaci.2006.12.609. PubMed PMID: 17336615;
- 652 26. Hunninghake GM, Soto-Quiros ME, Avila L, Kim HP, Lasky-Su J, Rafaels N, Ruczinski I, Beaty
653 TH, Mathias RA, Barnes KC, Wilk JB, O'Connor GT, Gauderman WJ, Vora H, Baurley JW, Gilliland F,
654 Liang C, Sylvia JS, Klanderman BJ, Sharma SS, Himes BE, Bossley CJ, Israel E, Raby BA, Bush A,
655 Choi AM, Weiss ST, Celedon JC. TSLP polymorphisms are associated with asthma in a sex-specific

- 656 fashion. *Allergy*. 2010;65(12):1566-75. Epub 2010/06/22. doi: 10.1111/j.1398-9995.2010.02415.x.
657 PubMed PMID: 20560908;
- 658 27. Litonjua AA, Lange NE, Carey VJ, Brown S, Laranjo N, Harshfield BJ, O'Connor GT, Sandel M,
659 Strunk RC, Bacharier LB, Zeiger RS, Schatz M, Hollis BW, Weiss ST. The Vitamin D Antenatal Asthma
660 Reduction Trial (VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D
661 supplementation in pregnancy for the primary prevention of asthma and allergies in children. *Contemp*
662 *Clin Trials*. 2014;38(1):37-50. Epub 2014/03/13. doi: 10.1016/j.cct.2014.02.006. PubMed PMID:
663 24614387;
- 664 28. Patil SU, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B, Virkud Y, Schneider M, Shreffler
665 WG. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after
666 peanut oral immunotherapy. *J Allergy Clin Immunol*. 2019;144(5):1310-9 e4. Epub 2019/08/05. doi:
667 10.1016/j.jaci.2019.07.028. PubMed PMID: 31377342;
- 668 29. Blumenthal MN, Banks-Schlegel S, Bleecker ER, Marsh DG, Ober C. Collaborative studies on
669 the genetics of asthma—National Heart, Lung and Blood Institute. *Clinical & Experimental Allergy*.
670 1995;25:29-32. doi: 10.1111/j.1365-2222.1995.tb00416.x;
- 671 30. Kelly RS, Virkud Y, Giorgio R, Celedon JC, Weiss ST, Lasky-Su J. Metabolomic profiling of lung
672 function in Costa-Rican children with asthma. *Biochim Biophys Acta Mol Basis Dis*. 2017;1863(6):1590-
673 5. Epub 2017/02/12. doi: 10.1016/j.bbadis.2017.02.006. PubMed PMID: 28188833;
- 674 31. Kelly RS, Sordillo JE, Lasky-Su J, Dahlin A, Perng W, Rifas-Shiman SL, Weiss ST, Gold DR,
675 Litonjua AA, Hivert MF, Oken E, Wu AC. Plasma metabolite profiles in children with current asthma.
676 *Clin Exp Allergy*. 2018;48(10):1297-304. Epub 2018/05/29. doi: 10.1111/cea.13183. PubMed PMID:
677 29808611;
- 678 32. Zhang B, Hu S, Baskin E, Patt A, Siddiqui JK, Mathe EA. RaMP: A Comprehensive Relational
679 Database of Metabolomics Pathways for Pathway Enrichment Analysis of Genes and Metabolites.
680 *Metabolites*. 2018;8(1). Epub 2018/02/23. doi: 10.3390/metabo8010016. PubMed PMID: 29470400;
- 681 33. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D,
682 Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K,
683 Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N,
684 Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L,
685 Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. *Nucleic*
686 *Acids Res*. 2007;35(Database issue):D521-6. Epub 2007/01/05. doi: 10.1093/nar/gkl923. PubMed
687 PMID: 17202168;
- 688 34. Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL,
689 Berjanskii M, Mah R, Yamamoto M, Jovel J, Torres-Calzada C, Hiebert-Giesbrecht M, Lui VW,
690 Varshavi D, Varshavi D, Allen D, Arndt D, Khetarpal N, Sivakumaran A, Harford K, Sanford S, Yee K,
691 Cao X, Budinski Z, Liigand J, Zhang L, Zheng J, Mandal R, Karu N, Dambrova M, Schioth HB, Greiner
692 R, Gautam V. HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Res*.
693 2022;50(D1):D622-D31. Epub 2022/01/07. doi: 10.1093/nar/gkab1062. PubMed PMID: 34986597;
- 694 35. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J,
695 Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S,
696 Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The reactome pathway
697 knowledgebase. *Nucleic Acids Res*. 2020;48(D1):D498-D503. Epub 2019/11/07. doi:
698 10.1093/nar/gkz1031. PubMed PMID: 31691815;
- 699 36. Agrawal A, Balci H, Hanspers K, Coort SL, Martens M, Slenter DN, Ehrhart F, Digles D,
700 Waagmeester A, Wassink I, Abbassi-Daloui T, Lopes EN, Iyer A, Acosta JM, Willighagen LG, Nishida K,
701 Riutta A, Basaric H, Evelo CT, Willighagen EL, Kutmon M, Pico AR. WikiPathways 2024: next
702 generation pathway database. *Nucleic Acids Res*. 2024;52(D1):D679-D89. Epub 2023/11/09. doi:
703 10.1093/nar/gkad960. PubMed PMID: 37941138;
- 704 37. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck
705 C, Subramanian S, Bolton E, Greiner R, Wishart DS. ClassyFire: automated chemical classification with

- 706 a comprehensive, computable taxonomy. *J Cheminform.* 2016;8:61. Epub 2016/11/22. doi:
707 10.1186/s13321-016-0174-y. PubMed PMID: 27867422;
- 708 38. R Core Team. R: A language and environment for statistical computing. R Foundation for
709 Statistical Computing [Internet]. 2018. Available from: <https://www.R-project.org/>.
- 710 39. dbGaP/database of Genotypes and Phenotypes/ National Center for Biotechnology Information,
711 National Library of Medicine (NCBI/NLM). Available from: <https://www.ncbi.nlm.nih.gov/gap>.
- 712 40. ECHO Cohort Data;
- 713 41. Metabolomics Workbench;
- 714 42. Lee SY, Park YM, Yoo HJ, Lee SH, Choi EJ, Baek EY, Song KB, Yoon J, Hong SJ. The
715 alternative bile acid pathway can predict food allergy persistence in early childhood. *Pediatr Allergy*
716 *Immunol.* 2023;34(8):e14003. Epub 2023/08/25. doi: 10.1111/pai.14003. PubMed PMID: 37622258;
- 717 43. Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. Intestinal Absorption of Bile Acids in
718 Health and Disease. *Compr Physiol.* 2019;10(1):21-56. Epub 2019/12/20. doi: 10.1002/cphy.c190007.
719 PubMed PMID: 31853951;
- 720 44. Calzadilla N, Comiskey SM, Dudeja PK, Saksena S, Gill RK, Alrefai WA. Bile acids as
721 inflammatory mediators and modulators of intestinal permeability. *Front Immunol.* 2022;13:1021924.
722 Epub 2022/12/27. doi: 10.3389/fimmu.2022.1021924. PubMed PMID: 36569849;
- 723 45. Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y,
724 Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR. Bile acid
725 metabolites control T(H)17 and T(reg) cell differentiation. *Nature.* 2019;576(7785):143-8. Epub
726 2019/11/30. doi: 10.1038/s41586-019-1785-z. PubMed PMID: 31776512;
- 727 46. Paik D, Yao L, Zhang Y, Bae S, D'Agostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco
728 J, Bisanz JE, Rakowski CK, Vlamakis H, Xavier RJ, Turnbaugh PJ, Longman RS, Krout MR, Clish CB,
729 Rastinejad F, Huttenhower C, Huh JR, Devlin AS. Human gut bacteria produce Tau(Eta)17-modulating
730 bile acid metabolites. *Nature.* 2022;603(7903):907-12. Epub 2022/03/18. doi: 10.1038/s41586-022-
731 04480-z. PubMed PMID: 35296854;
- 732 47. Kiriyama Y, Nochi H. The Role of Gut Microbiota-Derived Lithocholic Acid, Deoxycholic Acid
733 and Their Derivatives on the Function and Differentiation of Immune Cells. *Microorganisms.*
734 2023;11(11). Epub 2023/11/25. doi: 10.3390/microorganisms11112730. PubMed PMID: 38004742;
- 735 48. Chiang JY. Bile acid metabolism and signaling. *Compr Physiol.* 2013;3(3):1191-212. Epub
736 2013/07/31. doi: 10.1002/cphy.c120023. PubMed PMID: 23897684;
- 737 49. Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist
738 C, Kasper DL. Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell
739 homeostasis. *Nature.* 2020;577(7790):410-5. Epub 2019/12/27. doi: 10.1038/s41586-019-1865-0.
740 PubMed PMID: 31875848;
- 741 50. Luce S, Chinthrajah S, Lyu SC, Nadeau KC, Mascarell L. Th2A and Th17 cell frequencies and
742 regulatory markers as follow-up biomarker candidates for successful multifoed oral immunotherapy.
743 *Allergy.* 2020;75(6):1513-6. Epub 2020/01/14. doi: 10.1111/all.14180. PubMed PMID: 31930521;
- 744 51. Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M,
745 Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC,
746 Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT,
747 Wambre E, Impact. Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals
748 undergoing oral immunotherapy. *J Allergy Clin Immunol.* 2023;152(1):155-66 e9. Epub 2023/04/02. doi:
749 10.1016/j.jaci.2023.03.020. PubMed PMID: 37003475;
- 750 52. Lozano-Ojalvo D, Tyler SR, Aranda CJ, Wang J, Sicherer S, Sampson HA, Wood RA, Burks
751 AW, Jones SM, Leung DYM, de Lafaille MC, Berin MC. Allergen recognition by specific effector Th2
752 cells enables IL-2-dependent activation of regulatory T-cell responses in humans. *Allergy.*
753 2023;78(3):697-713. Epub 2022/09/13. doi: 10.1111/all.15512. PubMed PMID: 36089900;
- 754 53. Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H,
755 O'Riordan G, Galli SJ, Nadeau KC. Peanut oral immunotherapy results in increased antigen-induced
regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). *J Allergy Clin*

- 757 Immunol. 2014;133(2):500-10. Epub 2014/03/19. doi: 10.1016/j.jaci.2013.12.1037. PubMed PMID:
758 24636474;
- 759 54. Berdyshev E, Goleva E, Bronova I, Bronoff AS, Hoffman BC, Ramirez-Gama MA, Garcia SL,
760 Crumrine D, Elias PM, Cho CB, Leung DYM. Unique skin abnormality in patients with peanut allergy
761 but no atopic dermatitis. *J Allergy Clin Immunol.* 2021;147(1):361-7 e1. Epub 2020/07/03. doi:
762 10.1016/j.jaci.2020.06.015. PubMed PMID: 32615171;
- 763 55. Correale J, Farez MF. Modulation of multiple sclerosis by sunlight exposure: role of cis-urocanic
764 acid. *J Neuroimmunol.* 2013;261(1-2):134-40. Epub 2013/06/27. doi: 10.1016/j.jneuroim.2013.05.014.
765 PubMed PMID: 23800457;
- 766 56. Holan V, Kuffova L, Zajicova A, Krulova M, Filipec M, Holler P, Jancarek A. Urocanic acid
767 enhances IL-10 production in activated CD4+ T cells. *J Immunol.* 1998;161(7):3237-41. Epub
768 1998/10/06. PubMed PMID: 9759837;
- 769 57. Lessie TG, Neidhardt FC. Formation and operation of the histidine-degrading pathway in
770 *Pseudomonas aeruginosa*. *J Bacteriol.* 1967;93(6):1800-10. Epub 1967/06/01. doi:
771 10.1128/jb.93.6.1800-1810.1967. PubMed PMID: 4290562;
- 772 58. Hart PH, Norval M. The Multiple Roles of Urocanic Acid in Health and Disease. *J Invest*
773 *Dermatol.* 2021;141(3):496-502. Epub 2020/09/14. doi: 10.1016/j.jid.2020.07.017. PubMed PMID:
774 32919759;
- 775 59. Sutherland DB, Suzuki K, Fagarasan S. Fostering of advanced mutualism with gut microbiota by
776 Immunoglobulin A. *Immunol Rev.* 2016;270(1):20-31. Epub 2016/02/13. doi: 10.1111/imr.12384.
777 PubMed PMID: 26864102;
- 778 60. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and
779 disease. *Cell Res.* 2020;30(6):492-506. Epub 2020/05/21. doi: 10.1038/s41422-020-0332-7. PubMed
780 PMID: 32433595;
- 781 61. Huffaker MF, Kanchan K, Bahnson HT, Baloh C, Lack G, Nepom GT, Mathias RA. Incorporating
782 genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the
783 genetic findings from the LEAP trial. *J Allergy Clin Immunol.* 2023;151(4):841-7. Epub 2023/02/03. doi:
784 10.1016/j.jaci.2022.12.819. PubMed PMID: 36732171;
- 785 62. Politi E, Angelakopoulou A, Grapsa D, Zande M, Stefanaki K, Panagiotou I, Roma E, Syrigou E.
786 Filaggrin and Periostin Expression Is Altered in Eosinophilic Esophagitis and Normalized With
787 Treatment. *J Pediatr Gastroenterol Nutr.* 2017;65(1):47-52. Epub 2017/06/24. doi:
788 10.1097/MPG.0000000000001419. PubMed PMID: 28644349;
- 789 63. Nagano N, Araki A, Ishikawa N, Nagase M, Adachi K, Ishimura N, Ishihara S, Kinoshita Y,
790 Maruyama R. Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-
791 responders compared with proton pump inhibitor responders of eosinophilic esophagitis. *Esophagus.*
792 2021;18(2):362-71. Epub 2020/09/11. doi: 10.1007/s10388-020-00781-2. PubMed PMID: 32909083;
- 793 64. Wright BL, Fernandez-Becker NQ, Kambham N, Purington N, Cao S, Tupa D, Zhang W,
794 Sindher SB, Rank MA, Kita H, Katzka DA, Shim KP, Bunning BJ, Doyle AD, Jacobsen EA, Tsai M,
795 Boyd SD, Manohar M, Chinthrajah RS. Gastrointestinal Eosinophil Responses in a Longitudinal,
796 Randomized Trial of Peanut Oral Immunotherapy. *Clin Gastroenterol Hepatol.* 2021;19(6):1151-9 e14.
797 Epub 2020/05/21. doi: 10.1016/j.cgh.2020.05.019. PubMed PMID: 32434067;
- 798 65. Duan J, Song Y, Zhang X, Wang C. Effect of omega-3 Polyunsaturated Fatty Acids-Derived
799 Bioactive Lipids on Metabolic Disorders. *Front Physiol.* 2021;12:646491. Epub 2021/06/12. doi:
800 10.3389/fphys.2021.646491. PubMed PMID: 34113260;
- 801 66. Mitson-Salazar A, Yin Y, Wansley DL, Young M, Bolan H, Arceo S, Ho N, Koh C, Milner JD,
802 Stone KD, Wank SA, Prussin C. Hematopoietic prostaglandin D synthase defines a proeosinophilic
803 pathogenic effector human T(H)2 cell subpopulation with enhanced function. *J Allergy Clin Immunol.*
804 2016;137(3):907-18 e9. Epub 2015/10/04. doi: 10.1016/j.jaci.2015.08.007. PubMed PMID: 26431580;
- 805 67. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, Gersuk VH, DeBerg HA,
806 Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW. A
807 phenotypically and functionally distinct human T(H)2 cell subpopulation is associated with allergic

- 808 disorders. *Sci Transl Med*. 2017;9(401). Epub 2017/08/05. doi: 10.1126/scitranslmed.aam9171.
809 PubMed PMID: 28768806;
- 810 68. Morgan DM, Ruitter B, Smith NP, Tu AA, Monian B, Stone BE, Virk-Hundal N, Yuan Q, Shreffler
811 WG, Love JC. Clonally expanded, GPR15-expressing pathogenic effector T(H)2 cells are associated
812 with eosinophilic esophagitis. *Sci Immunol*. 2021;6(62). Epub 2021/08/15. doi:
813 10.1126/sciimmunol.abi5586. PubMed PMID: 34389613;
- 814 69. Bertschi NL, Bazzini C, Schlapbach C. The Concept of Pathogenic TH2 Cells: Collegium
815 Internationale Allergologicum Update 2021. *Int Arch Allergy Immunol*. 2021;182(5):365-80. Epub
816 2021/04/13. doi: 10.1159/000515144. PubMed PMID: 33845475;
- 817 70. Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, Joseph J, Gertie JA, Xu L, Collet
818 MA, Grassmann JDS, Simoneau T, Chiang D, Berin MC, Craft JE, Weinstein JS, Williams A,
819 Eisenbarth SC. Identification of a T follicular helper cell subset that drives anaphylactic IgE. *Science*.
820 2019;365(6456). Epub 2019/08/03. doi: 10.1126/science.aaw6433. PubMed PMID: 31371561;
- 821 71. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, Gersuk VH, DeBerg HA,
822 Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW. A
823 phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic
824 disorders. *Sci Transl Med*. 2017;9(401). doi: 10.1126/scitranslmed.aam9171. PubMed PMID:
825 28768806;
- 826 72. Micosse C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, Seyed Jafari SM, Olah P,
827 Yawalkar N, Simon D, Borradori L, Kuchen S, Yerly D, Homey B, Conrad C, Snijder B, Schmidt M,
828 Schlapbach C. Human "T(H)9" cells are a subpopulation of PPAR-gamma(+) T(H)2 cells. *Sci Immunol*.
829 2019;4(31). Epub 2019/01/20. doi: 10.1126/sciimmunol.aat5943. PubMed PMID: 30658968;
- 830 73. Jang H, Kim EG, Kim M, Kim SY, Kim YH, Sohn MH, Kim KW. Metabolomic profiling revealed
831 altered lipid metabolite levels in childhood food allergy. *J Allergy Clin Immunol*. 2022;149(5):1722-31
832 e9. Epub 2021/11/30. doi: 10.1016/j.jaci.2021.10.034. PubMed PMID: 34843802;

833